Rovi's flagship product Bemiparin is present in 89 countries, and the company markets an enoxaparin biosimilar developed in-house across 38 countries. Rovi continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. The company leverages vertical integration, proprietary manufacturing capabilities, and international expansion to compete in competitive specialty pharma and contract manufacturing markets.
Cyborg Score Rationale
In 2024, revenue declined 7.93% to €763.75M and earnings fell 19.64% to €136.88M. Positive interest cover and low net debt to EBITDA of 0.40 support financial stability, with EBIT covering interest expense 69.7 times over. However, profitability headwinds and cash conversion challenges offset these strengths.
Top Insights
EBIT declined 16% year-over-year; repeated performance like this could lead to stock difficulties.
In Q1 2025, the company obtained positive results in two phase one trials, enabling progress towards phase III clinical trials for ISM platform formulations.
The company offers contract-manufacturing services including aseptic filling, terminal sterilization, labeling, and serialization for injectable pharmaceutical forms and solid products.
With 40+ marketed products and geographic presence across Europe, Rovi has diversified revenue streams reducing single-product concentration risk.
Named Competitors
Specialty Pharma Portfolio — Spanish pharmaceutical competitor in dermatology and respiratory
Specialty Pharma & Generics — Spanish pharmaceutical company in specialty and generic markets
Contract Manufacturing & Pharma — European pharma and contract manufacturing player
Biosimilars & Injectables — Larger Spanish pharma/biotech company in plasma products and injectables
Recent Developments
(Q1 2025) Positive Phase I trial results for ISM platform-based formulations with progress to Phase III trials
(2024) Revenue declined to €763.75M (-7.93% YoY) amid market and competitive pressures
(2024) Earnings fell to €136.88M (-19.64% YoY) reflecting margin compression
Open the full interactive Laboratorios Farmaceuticos Rovi report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.